drugset
drugset / Trial / NCT07818330

A Repeat Dose Study of the Dexmedetomidine Transdermal System in Healthy Subjects

NCT07818330 ↗

Phase 1 Not yet recruiting 20 enrolled Teikoku Pharma USA, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This Phase 1, 16-day Repeat dose study will evaluate the safety of a Dexmedetomidine Transdermal System (DMTS) skin system in healthy adults Subjects. Participants will receive the patch for four consecutive 4-day treatment periods. Researchers will monitor safety, drug levels in the blood, sedation effects, skin irritation, and how well the patch stays attached to the skin.

Timeline

Start
2026-10-30
Primary completion
2026-12-09
Completion
2026-12-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmedetomidine Other / unclassified 2.92 mg Other

Indications

No indication recorded.